跳至主要内容
临床试验/ISRCTN65030013
ISRCTN65030013进行中(未招募)未知

Therapy Personalisation using Multiomic Analyses in Inflammatory Bowel Disease – THAMES-IBD

Imperial College London0 个研究点目标入组 468 人开始时间: 2022年6月23日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
468

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Healthy control patients:
  • 1.1. =18 years-old
  • 1.2. Willing to consent to sample collection
  • 1.3. No prior diagnosis or current clinical suspicion of IBD
  • 2. Inflammatory bowel disease patients, including ulcerative colitis, Crohn’s disease and IBD-unclassified
  • 2.1. Active disease as determined by standard clinical parameters measured within the 2 months prior to recruitment:
  • - Crohn's symptom flare as indicated by Harvey-Bradshaw score >5 or unweighted PRO-2 (CD) of average daily stool stool frequency (SF) score =4 and/or average daily abdominal pain (AP) score =2,
  • - faecal calprotectin =250micrograms/gram;
  • - UC / IBD-U symptom flare as indicated by PRO-2 (UC) of =3 including a rectal bleeding score of =1,
  • - faecal calprotectin =250micrograms/gram.
  • 3. Able to consent to the study (with interpreter, if required)

排除标准

  • Unable or unwilling to provide informed consent

研究者

相似试验